Physician profile
Simon N Mcrae
NPI 1992774723
$2,012.51
in general payments reported to CMS, 2019-2025
27 companies · $354 in 2025
The $354 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $204 · 2021: $194 · 2022: $403 · 2023: $227 · 2024: $278 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $859.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $394.05 | 2022-2025 | |
| Astellas Pharma US INC | $332.64 | 2019-2024 | Xtandi, Myrbetriq |
| Janssen Biotech, INC. | $134.02 | 2019-2025 | Erleada, Akeega |
| Boston Scientific Corporation | $123.32 | 2020-2023 | Lithovue |
| Pfizer INC. | $122.01 | 2020-2024 | |
| Laborie Medical Technologies Corp. | $107.60 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Merck Sharp & Dohme LLC | $76.47 | 2019-2020 | |
| Urogen Pharma, INC. | $75.14 | 2021-2023 | Jelmyto |
| Astrazeneca Pharmaceuticals LP | $63.76 | 2020-2025 | Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $63.07 | 2019-2022 | |
| Abbvie INC. | $54.74 | 2022-2023 | |
| Endo Pharmaceuticals INC. | $52.98 | 2019-2021 | |
| Tolmar, INC. | $50.00 | 2024-2025 | Eligard, Jatenzo |
| Incyte Corporation | $39.05 | 2019 | |
| Astellas Pharma Global Development | $37.48 | 2024 | Xtandi |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $35.09 | 2025 | Nimbl, Flexitouch Plus |
| Karl Storz Endoscopy-America | $27.43 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.79 | 2019 | |
| Alexion Pharmaceuticals, INC. | $24.98 | 2019 | |
| Sumitomo Pharma America, INC. | $24.98 | 2025 | Orgovyx |
| Myovant Sciences INC. | $24.18 | 2021 | |
| Eisai INC. | $24.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.32 | 2019 | |
| Progenics Pharmaceuticals, INC. | $23.11 | 2024 | |
| Seagen INC. | $18.11 | 2019 | |
| Coloplast Corp | $17.12 | 2025 | |
| Lilly USA, LLC | $17.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Mcrae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.